Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From Inositec AG

CSL Makes $11.7bn Move On Vifor Pharma In Renal Disease Push

Confirming rumors of an acquisition, CSL will venture into some new territories as well as boost its renal franchise when it takes over Switzerland’s Vifor Pharma in a deal worth $11.7bn.

Companies Deals

Vifor Bulks Up Renal Franchise With Sanifit And Inositec Acquisitions

A couple of months after licensing the late-stage kidney disease drug sparsentan from Travere, the Swiss group has beefed up its nephrology activities by buying Mallorca-based Sanifit and Swiss outfit Inositec.

M & A Renal

Inositec CEO On 2017 Financing Plans

Mattias Ivarsson, co-founder and CEO of Swiss biotech company Inositec, talks to Lucie Ellis, senior writer at Scrip, about the company's technology and progress since being founded in 2015.

StartUps and SMEs Financing
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
UsernamePublicRestriction

Register